| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Strategic Planning > A Business Plan Can Secure Financing for a Professional Practice or Small to Mid Size Business |
|
E-Folder - A Business Plan Can Secure Financing for a Professional Practice or Small to Mid Size Business
Writing a business plan can be intimidating. It is however a necessary step towards earning a business loan for the launch or expansion of a professional practice or According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product small to mid size business. Gaining an understanding about the expectations that the bank, government or other type of investor have about the contents of your busi ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ness plan can help you to get started. The following is a comprehensive list of the basic components of a business plan focused on securing financing: lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. xecutive summary
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe e business offers
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro >
A mission statement is a single sentence that communicates the core values of the practice or business. It establishes the reason for being for the organiz ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc tion.
A vision statement is a single statement that communicates business goals for the next 3-5 years in terms of the most appropriate benchmarks whether they are m easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi arket share, reputation or financial. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically management team as well as the projected costs of the employees:
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi pertise as well as comprehension of the changing dynamics of the marketplace:
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a rengths, weaknesses, opportunities and threats
dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod evant to a business plan whether it accounts for traditional or non-traditional promotional types of activities:
cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin service, promotional activity, location, fees
tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen r business may account for standard, special or proprietary processes:
t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel statements enclosed within your business plan need to be achievable rather than overly optimistic:
ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust iled profit and loss statement
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products usiness and how you expect to handle them. It should detail the core strategies you plan to employ in order to mitigate risks.
Remember that the objective of . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de your business plan is to communicate why you are a good candidate for this business loan. Ideally your business plan will have demonstrated expertise accompanied by elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip achievable sales projections, key ingredients to developing the perception that your business is a low risk investment to a bank, government or other type of investor tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Defining a R&D Framework for Entrepreneurship and Innovation on Information Product Generation Track Employee Output & Not Time What Type of Advertising Suits a Small Business?
|